BioSpace News Archive

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, August 2, 2021 at 8:30 AM ET to discuss results for the second quarter 2021 and provide a business outlook for the remainder of the year.

Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced it will report financial results for the second quarter 2021 and provide a corporate update at 4:30 p.m. ET on August 4, 2021.

Abeona Therapeutics Inc., a fully-integrated leader in gene and cell therapy, announced that the Company completed a successful Type B meeting with the U.S. Food and Drug Administration regarding the pivotal trial to support filing and approval for its AAV-based gene therapy ABO-102 for the treatment of patients with Sanfilippo syndrome type A.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming second quarter 2021 earnings call and webcast, reporting financial results for the quarter ended June 30, 2021

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its first quarter 2021 financial results will be released after the market closes on Wednesday, August 4, 2021.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), today announced that its President and CEO, Glenn Mattes, will be available for one-on-one meetings and will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 2:00pm EST.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the last patient has completed their planned Week-24 follow-up visit in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical gel with antiviral properties for the treatment of molluscum contagiosum (“molluscum”).

Products and services offered by players in the global dental insurance market i.e. the dental insurance services is a health insurance specifically designed for the purpose of dental care.

A Fact.MR survey on dental membrane and bone graft substitutes market offers detailed analysis on the key growth drivers and trends affecting demand in the market.

A Fact.MR survey on dental infection control products market offers detailed analysis on growth drivers and trends affecting demand in terms of product, equipment, and region.